HNF4A and metabolic dysfunction-associated steatotic liver disease: In contrast to hyperlipidemia in NAFLD, hypolipidemia often occurs in patients with end-stage liver diseases, such as cirrhosis and liver cancer [10], in which the loss of functional HNF4α is more marked [11] and may be better mimicked by the use of HNF4α KO mice.